| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,745 | -19,601 |
| Depreciation and amortization | 1,036 | 746 |
| Stock-based compensation expense | 1,741 | 1,334 |
| Accretion of discount on marketable securities | 509 | 379 |
| Gain on sale of property and equipment | 288 | 288 |
| Non-cash lease expense | 1,875 | 1,239 |
| Prepaid expenses and other assets | 322 | 236 |
| Accounts payable and accrued expenses | -5,233 | -3,351 |
| Operating lease liabilities | -1,620 | -1,026 |
| Deferred revenue | -2,762 | -1,533 |
| Other long-term liabilities | 133 | 133 |
| Net cash used in operating activities | -32,694 | -22,962 |
| Purchases of property and equipment | 72 | - |
| Proceeds from sales of property and equipment | 963 | 963 |
| Purchases of marketable securities | 17,176 | 15,457 |
| Maturities of marketable securities | 59,513 | 39,838 |
| Net cash provided by investing activities | 43,228 | 25,344 |
| Proceeds from issuance of common stock | 14 | 14 |
| Net cash provided by financing activities | 14 | 14 |
| Net increase (decrease) in cash | 10,548 | 2,396 |
| Cash and cash equivalents at beginning of period | 8,970 | - |
| Cash and cash equivalents at end of period | 19,518 | - |
Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. (BOLT)